Harrow Inc Dossier - Source-backed chat

Harrow Inc

HROWNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $30.61Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.1B

Enterprise Value $1.4B

Shares Outstanding 37.7M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Harrow, Inc. (HROW) has built a robust commercial ophthalmology platform with high-growth assets like VEVYE, IHEEZO, and TRIESENCE. However, Q1 2026 results highlighted significant execution and forecasting risks, characterized by a widening GAAP net loss and an $8 million gross-to-net adjustment on VEVYE. While underlying prescription demand remains strong and management has reaffirmed its ambitious FY 2026 guidance ($350M–$365M revenue), the stock's current valuation already prices in a successful second-half turnaround. Given the steep ramp required to meet full-year targets and elevated financial leverage, a Hold rating is warranted until commercial execution and EBITDA recovery become visible.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$59.00

Mean target$67.50

High · most bullish analyst$88.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$59.00

The bear case is triggered by persistent gross-to-net pricing pressure on VEVYE, slower-than-expected market penetration of IHEEZO, and supply chain or regulatory setbacks at the New Jersey 503B outsourcing facility. Under this scenario, Harrow misses its FY 2026 guidance, cash burn intensifies, and the company's high debt burden ($300.67 million as of Q1 2026) limits financial flexibility, forcing dilutive capital raises or restrictive debt covenants.

Base CaseCentral scenario

$67.50

Matches the consensus mean

The base case assumes Harrow successfully stabilizes VEVYE's pricing model and achieves steady sequential growth, though full-year 2026 revenue is likely to land near the lower end of the guided range ($350 million). Operating leverage begins to manifest in late 2026 as the expanded sales force matures, leading to positive Adjusted EBITDA in the second half of the year. MELT-300 remains on track for a Q1 2027 NDA submission.

Bull CaseUpside scenario

$88.00

The bull case assumes rapid resolution of VEVYE's gross-to-net issues, leading to preferred PBM status conversion and over $100 million in VEVYE sales for 2026. Additionally, IHEEZO achieves a 20-25% net pricing improvement in H2 2026, and the re-launch of VERKAZIA and BYOOVIZ drives substantial high-margin revenue. Under this scenario, Harrow successfully meets the upper end of its FY 2026 guidance and progresses smoothly toward its target of a $250 million quarterly revenue run rate by the end of 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong underlying volume demand with VEVYE achieving a 14% branded dry eye market share and surpassing Xiidra in total prescriptions.
Diversified ophthalmic portfolio addressing multi-billion-dollar markets, supported by a newly doubled dry eye sales force and tripled surgical sales force.
Late-stage pipeline optionality with MELT-300 targeting the multi-billion-dollar non-opioid procedural sedation market.

Key Investment Risks

High concentration of revenue in a few key branded assets, making the company highly vulnerable to pricing and reimbursement changes.
Significant execution risk associated with a heavily back-end loaded FY 2026 guidance ramp.
Elevated financial leverage with $300.67 million in total debt against a negative Adjusted EBITDA of -$12.7 million in Q1 2026.

Thesis Invalidation Triggers

A downward revision of the FY 2026 revenue guidance range ($350M–$365M) during subsequent quarterly reports.
Failure to achieve positive Adjusted EBITDA by Q3 2026.
Regulatory delays or an FDA Refusal to File letter for the MELT-300 NDA in early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.